Anifrolumab: first biologic approved in the EU not restricted to patients with a high degree of disease activity for the treatment of moderate to severe systemic lupus erythematosus

References

• Tsokos GC. Systemic lupus erythematosus. N Engl J Med. 2011;365(22):2110–2121. doi: 10.1056/NEJMra1100359
   PubMed Web of Science ®Google Scholar
• Scherlinger M, Mertz P, Sagez F, et al. Worldwide trends in all-cause mortality of auto-immune systemic diseases between 2001 and 2014. Autoimmun Rev. 2020;19(6):102531. doi: 10.1016/j.autrev.2020.102531
   PubMed Web of Science ®Google Scholar
• Tselios K, Gladman DD, Sheane BJ, et al. All-cause, cause-specific and age-specific standardised mortality ratios of patients with systemic lupus erythematosus in Ontario, Canada over 43 years (1971–2013). Ann Rheum Dis. 2019;78(6):802–806. doi: 10.1136/annrheumdis-2018-214802
   PubMed Web of Science ®Google Scholar
• Barber MRW, Drenkard C, Falasinnu T, et al. Global epidemiology of systemic lupus erythematosus. Nat Rev Rheumatol. 2021;17(9):515–532. doi: 10.1038/s41584-021-00668-1
   PubMed Web of Science ®Google Scholar
• Furie R, Petri M, Zamani O, et al. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum. 2011;63(12):3918–3930. doi: 10.1002/art.30613
   PubMed Web of Science ®Google Scholar
• Harley ITW, Kaufman KM, Langefeld CD, et al. Genetic susceptibility to lupus: new insights from fine mapping and genome-wide association studies. Nat Rev Genet. 2009;10(5):285–290. doi: 10.1038/nrg2571
   PubMed Web of Science ®Google Scholar
• Bengtsson AA, Sturfelt G, Truedsson L, et al. Activation of type I interferon system in systemic lupus erythematosus correlates with disease activity but not with antiretroviral antibodies. Lupus. 2000;9(9):664–671. doi: 10.1191/096120300674499064
   PubMed Web of Science ®Google Scholar
• Oke V, Gunnarsson I, Dorschner J, et al. High levels of circulating interferons type I, type II and type III associate with distinct clinical features of active systemic lupus erythematosus. Arthritis Res Ther. 2019;21(1):107. doi: 10.1186/s13075-019-1878-y
   PubMedGoogle Scholar
• Niewold TB, Hua J, Lehman TJA, et al. High serum IFN-α activity is a heritable risk factor for systemic lupus erythematosus. Genes Immun. 2007;8(6):492–502. doi: 10.1038/sj.gene.6364408
   PubMed Web of Science ®Google Scholar
• Kirou KA, Lee C, George S, et al. Activation of the interferon-α pathway identifies a subgroup of systemic lupus erythematosus patients with distinct serologic features and active disease. Arthritis Rheum. 2005;52(5):1491–1503. doi: 10.1002/art.21031
   PubMed Web of Science ®Google Scholar
• Bennett L, Palucka AK, Arce E, et al. Interferon and granulopoiesis signatures in systemic lupus erythematosus blood. J Exp Med. 2003;197(6):711–723. doi: 10.1084/jem.20021553
   PubMed Web of Science ®Google Scholar
• Baechler EC, Batliwalla FM, Karypis G, et al. Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc Natl Acad Sci U S A. 2003;100(5):2610–2615. doi: 10.1073/pnas.0337679100
   PubMed Web of Science ®Google Scholar
• Houssiau FA, Thanou A, Mazur M, et al. IFN-α kinoid in systemic lupus erythematosus: results from a phase IIb, randomised, placebo-controlled study. Ann Rheumatic Dis. 2020;79(3):347–355. doi: 10.1136/annrheumdis-2019-216379
   PubMed Web of Science ®Google Scholar
• Lauwerys BR, Hachulla E, Spertini F, et al. Down-regulation of interferon signature in systemic lupus erythematosus patients by active immunization with interferon α-kinoid. Arthritis Rheum. 2013;65(2):447–456. doi: 10.1002/art.37785
   PubMed Web of Science ®Google Scholar
• Kalunian KC, Merrill JT, Maciuca R, et al. A phase II study of the efficacy and safety of rontalizumab (rhuMab interferon-α) in patients with systemic lupus erythematosus (ROSE). Ann Rheum Dis. 2016;75(1):196–202. doi: 10.1136/annrheumdis-2014-206090
   PubMed Web of Science ®Google Scholar
• Khamashta M, Merrill JT, Werth VP, et al. Sifalimumab, an anti-interferon-α monoclonal antibody, in moderate to severe systemic lupus erythematosus: a randomised, double-blind, placebo-controlled study. Ann Rheum Dis. 2016;75(11):1909–1916. doi: 10.1136/annrheumdis-2015-208562
   PubMed Web of Science ®Google Scholar
• Fanouriakis A, Kostopoulou M, Alunno A, et al. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis. 2019;78(6):736–745. doi: 10.1136/annrheumdis-2019-215089
   PubMed Web of Science ®Google Scholar
• Riggs JM, Hanna RN, Rajan B, et al. Characterisation of anifrolumab, a fully human anti-interferon receptor antagonist antibody for the treatment of systemic lupus erythematosus. Lupus Sci Med. 2018;5(1):e000261. doi: 10.1136/lupus-2018-000261
   PubMed Web of Science ®Google Scholar
• Oganesyan V, Gao C, Shirinian L, et al. Structural characterization of a human Fc fragment engineered for lack of effector functions. Acta Crystallogr D Biol Crystallogr. 2008;64(6):700–704. doi: 10.1107/S0907444908007877
   PubMedGoogle Scholar
• Furie R, Khamashta M, Merrill JT, et al. Anifrolumab, an anti–Interferon-α receptor monoclonal antibody, in moderate-to-severe systemic lupus erythematosus. Arthritis & Rheumat. 2017;69(2):376–386. doi: 10.1002/art.39962
   PubMed Web of Science ®Google Scholar
• Furie RA, Morand EF, Bruce IN, et al. Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): a randomised, controlled, phase 3 trial. Lancet Rheumatol. 2019;1(4):e208–e219. doi: 10.1016/S2665-9913(19)30076-1
   PubMedGoogle Scholar
• Morand EF, Furie R, Tanaka Y, et al. Trial of anifrolumab in active systemic lupus erythematosus. N Engl J Med. 2020;382(3):211–221. doi: 10.1056/NEJMoa1912196
   PubMed Web of Science ®Google Scholar
• Casey KA, Guo X, Smith MA, et al. Type I interferon receptor blockade with anifrolumab corrects innate and adaptive immune perturbations of SLE. Lupus Sci Med. 2018;5(1):e000286. doi: 10.1136/lupus-2018-000286
   PubMed Web of Science ®Google Scholar
• Goldberg A, Geppert T, Schiopu E, et al. Dose-escalation of human anti-interferon-α receptor monoclonal antibody MEDI-546 in subjects with systemic sclerosis: a phase 1, multicenter, open label study. Arthritis Res Ther. 2014;16(1):R57. doi: 10.1186/ar4492
   PubMed Web of Science ®Google Scholar
• Chia YL, Santiago L, Wang B, et al. Exposure–response analysis for selection of optimal dosage regimen of anifrolumab in patients with systemic lupus erythematosus. Rheumatology (Oxford). 2021;60(12):5854–5862. doi: 10.1093/rheumatology/keab176
   PubMed Web of Science ®Google Scholar
• Almquist J, Kuruvilla D, Mai T, et al. Nonlinear population pharmacokinetics of anifrolumab in healthy volunteers and patients with systemic lupus erythematosus. J Clin Pharmacol. 2022;62(9):1106–1120. doi: 10.1002/jcph.2055
   PubMed Web of Science ®Google Scholar
• Tanaka Y, Takeuchi T, Okada M, et al. Safety and tolerability of anifrolumab, a monoclonal antibody targeting type I interferon receptor, in Japanese patients with systemic lupus erythematosus: a multicenter, phase 2, open-label study. Mod Rheumatol. 2020;30(1):101–108. doi: 10.1080/14397595.2019.1583833
   PubMed Web of Science ®Google Scholar
• Chia YL, Zhang J, Tummala R, et al. Relationship of anifrolumab pharmacokinetics with efficacy and safety in patients with systemic lupus erythematosus. Rheumatology (Oxford). 2022;61(5):1900–1910. doi: 10.1093/rheumatology/keab704
   PubMed Web of Science ®Google Scholar
• Jayne D, Rovin B, Mysler EF, et al. Phase II randomised trial of type I interferon inhibitor anifrolumab in patients with active lupus nephritis. Ann Rheum Dis. 2022;81(4):496–506. doi: 10.1136/annrheumdis-2021-221478
   PubMed Web of Science ®Google Scholar
• Tummala R, Rouse T, Berglind A, et al. Safety, tolerability and pharmacokinetics of subcutaneous and intravenous anifrolumab in healthy volunteers. Lupus Sci Med. 2018;5(1):e000252. doi: 10.1136/lupus-2017-000252
   PubMed Web of Science ®Google Scholar
• Vital EM, Merrill JT, Morand EF, et al. Anifrolumab efficacy and safety by type I interferon gene signature and clinical subgroups in patients with SLE: post hoc analysis of pooled data from two phase III trials. Ann Rheum Dis. 2022;81(7):951–961. doi: 10.1136/annrheumdis-2021-221425
   PubMed Web of Science ®Google Scholar
• Morand EF, Furie RA, Bruce IN, et al. Efficacy of anifrolumab across organ domains in patients with moderate-to-severe systemic lupus erythematosus: a post-hoc analysis of pooled data from the TULIP-1 and TULIP-2 trials. Lancet Rheumatol. 2022;4(4):e282–e292. doi: 10.1016/S2665-9913(21)00317-9
   PubMedGoogle Scholar
• Furie R, Morand EF, Askanase AD, et al. Anifrolumab reduces flare rates in patients with moderate to severe systemic lupus erythematosus. Lupus. 2021;30(8):1254–1263. doi: 10.1177/09612033211014267
   PubMed Web of Science ®Google Scholar
• Tummala R, Abreu G, Pineda L, et al. Safety profile of anifrolumab in patients with active SLE: an integrated analysis of phase II and III trials. Lupus Sci Med. 2021;8(1):e000464. doi: 10.1136/lupus-2020-000464
   PubMed Web of Science ®Google Scholar
• Chatham WW, Furie R, Saxena A, et al. Long-term safety and efficacy of anifrolumab in adults with systemic lupus erythematosus: results of a phase II open-label extension study. Arthritis & rheumat. 2021;73(5):816–825. doi: 10.1002/art.41598
   PubMed Web of Science ®Google Scholar
• Breillat P, Mathian A, Rozenberg F, et al. Is there an increased risk of severe COVID-19 among patients with systemic lupus erythematosus treated with anifrolumab? Lupus. 2023;32(3):453–455. doi: 10.1177/09612033231153536
   PubMed Web of Science ®Google Scholar
• Kalunian KC, Furie R, Morand EF, et al. A randomized, placebo-controlled phase III extension trial of the long-term safety and tolerability of anifrolumab in active systemic lupus erythematosus. Arthritis & Rheumat. 2023;75(2):253–265. doi: 10.1002/art.42392
   PubMed Web of Science ®Google Scholar
• Lazaro E, Scherlinger M, Truchetet M-E, et al. Biotherapies in systemic lupus erythematosus: new targets. Joint Bone Spine. 2017;84(3):267–274. doi: 10.1016/j.jbspin.2016.07.004
   PubMed Web of Science ®Google Scholar
• Blanco P, Palucka AK, Gill M, et al. Induction of dendritic cell differentiation by IFN-α in systemic lupus erythematosus. Science. 2001;294(5546):1540–1543. doi: 10.1126/science.1064890
   PubMed Web of Science ®Google Scholar
• Gensous N, Boizard-Moracchini A, Lazaro E, et al. Update on the cellular pathogenesis of lupus. Curr Opin Rheumatol. 2021;33(2):190–196. doi: 10.1097/BOR.0000000000000775
   PubMed Web of Science ®Google Scholar
• Bruce IN, O’Keeffe AG, Farewell V, et al. Factors associated with damage accrual in patients with systemic lupus erythematosus: results from the Systemic Lupus International Collaborating Clinics (SLICC) inception cohort. Ann Rheum Dis. 2015;74(9):1706–1713. doi: 10.1136/annrheumdis-2013-205171
   PubMed Web of Science ®Google Scholar
• Segura BT, Bernstein BS, McDonnell T, et al. Damage accrual and mortality over long-term follow-up in 300 patients with systemic lupus erythematosus in a multi-ethnic British cohort. Rheumatology (Oxford). 2020;59(3):698–698. doi: 10.1093/rheumatology/kez516
   PubMed Web of Science ®Google Scholar
• Mackensen A, Müller F, Mougiakakos D, et al. Author correction: anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus. Nat Med. 2022;1–9.
   PubMed Web of Science ®Google Scholar
• Gensous N, Vagner D, Barnetche T, et al. Galectin 9, CXCL-10 and tumor necrosis factor receptor type II as biomarkers of disease activity in systemic lupus erythematosus. Joint Bone Spine. 2021;89(3):105311. doi: 10.1016/j.jbspin.2021.105311
   PubMed Web of Science ®Google Scholar
• Rodríguez-Carrio J, Burska A, Conaghan PG, et al. Association between type I interferon pathway activation and clinical outcomes in rheumatic and musculoskeletal diseases: a systematic literature review informing EULAR points to consider. RMD Open. 2023;9(1):e002864. doi: 10.1136/rmdopen-2022-002864
   PubMed Web of Science ®Google Scholar
• Rodríguez-Carrio J, Burska A, Conaghan PG, et al. 2022 EULAR points to consider for the measurement, reporting and application of IFN-I pathway activation assays in clinical research and practice. Ann Rheum Dis. 2023;82(6):754–762. doi: 10.1136/ard-2022-223628
   PubMed Web of Science ®Google Scholar
• Fanouriakis A, Kostopoulou M, Cheema K, et al. 2019 update of the Joint European League against Rheumatism and European renal association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of lupus nephritis. Ann Rheum Dis. 2020;6(2):e001263. doi: 10.1136/rmdopen-2020-001263
   Google Scholar
• Furie R, Rovin BH, Houssiau F, et al. Two-year, randomized, controlled trial of belimumab in lupus nephritis. N Engl J Med. 2020;383(12):1117–1128. doi: 10.1056/NEJMoa2001180
   PubMed Web of Science ®Google Scholar
• Rovin BH, Teng YKO, Ginzler EM, et al. Efficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 2021;397(10289):2070–2080. doi: 10.1016/S0140-6736(21)00578-X
   PubMed Web of Science ®Google Scholar
• van Vollenhoven RF, Petri MA, Cervera R, et al. Belimumab in the treatment of systemic lupus erythematosus: high disease activity predictors of response. Ann Rheum Dis. 2012;71(8):1343–1349. doi: 10.1136/annrheumdis-2011-200937
   PubMed Web of Science ®Google Scholar
• Carter LM, Wigston Z, Laws P, et al. Rapid efficacy of anifrolumab across multiple subtypes of recalcitrant cutaneous lupus erythematosus parallels changes in discrete subsets of blood transcriptomic and cellular biomarkers. Br J Dermatol. 2023;189(2):210–218. doi: 10.1093/bjd/ljad089
   PubMed Web of Science ®Google Scholar
• Trentin F, Tani C, Elefante E, et al. Treatment with anifrolumab for discoid lupus erythematosus. JAMA Dermatol. 2023;159(2):224–226. doi: 10.1001/jamadermatol.2022.5242
   PubMed Web of Science ®Google Scholar
• Shaw K, Sanchez-Melendez S, Taylor D, et al. Assessment of clinical response to anifrolumab in patients with refractory discoid lupus erythematosus. JAMA Dermatol. 2023;159(5):560–563. doi: 10.1001/jamadermatol.2023.0175
   PubMed Web of Science ®Google Scholar
• Furie R, Werth VP, Merola JF, et al. Monoclonal antibody targeting BDCA2 ameliorates skin lesions in systemic lupus erythematosus. J Clin Invest. 2019;129(3):1359–1371. doi: 10.1172/JCI124466
   PubMed Web of Science ®Google Scholar
• Werth VP, Furie RA, Romero-Diaz J, et al. Trial of anti-BDCA2 antibody Litifilimab for cutaneous lupus erythematosus. N Engl J Med. 2022;387(4):321–331. doi: 10.1056/NEJMoa2118024
   PubMed Web of Science ®Google Scholar
• Furie RA, van Vollenhoven RF, Kalunian K, et al. Trial of anti-BDCA2 antibody litifilimab for systemic lupus erythematosus. N Engl J Med. 2022;387(10):894–904. doi: 10.1056/NEJMoa2118025
   PubMed Web of Science ®Google Scholar
• Bruce IN, Golam S, Steenkamp J, et al. Indirect treatment comparison of anifrolumab efficacy versus belimumab in adults with systemic lupus erythematosus. J Comp Eff Res. 2022;11(10):765–777. doi: 10.2217/cer-2022-0040
   PubMed Web of Science ®Google Scholar
• Neupane B, Shukla P, Slim M, et al. Belimumab versus anifrolumab in adults with systemic lupus erythematosus: an indirect comparison of clinical response at 52 weeks. Lupus Sci Med. 2023;10(1):e000907. doi: 10.1136/lupus-2023-000907
   PubMed Web of Science ®Google Scholar
• Wallace DJ, Navarra S, Petri MA, et al. Safety profile of belimumab: pooled data from placebo-controlled phase 2 and 3 studies in patients with systemic lupus erythematosus. Lupus. 2013;22(2):144–154. doi: 10.1177/0961203312469259
   PubMed Web of Science ®Google Scholar
• Sheikh SZ, Scheinberg MA, Wei J-C, et al. Mortality and adverse events of special interest with intravenous belimumab for adults with active, autoantibody-positive systemic lupus erythematosus (BASE): a multicentre, double-blind, randomised, placebo-controlled, phase 4 trial. Lancet Rheumatol. 2021;3(2):e122–e130. doi: 10.1016/S2665-9913(20)30355-6
   PubMedGoogle Scholar